Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.

about

Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.

Item

http://www.wikidata.org/entity/Q49404537

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Long-term progression-free sur ...... rearrangement: a case report.

@en

Long-term progression-free sur ...... rearrangement: a case report.

@nl

type

Item

label

Long-term progression-free sur ...... rearrangement: a case report.

@en

Long-term progression-free sur ...... rearrangement: a case report.

@nl

prefLabel

Long-term progression-free sur ...... rearrangement: a case report.

@en

Long-term progression-free sur ...... rearrangement: a case report.

@nl

P1476

Long-term progression-free sur ...... rearrangement: a case report.

@en

P2093

Jing Zhang

http://www.w3.org/2001/XMLSchema#string

Jingwen Xia

http://www.w3.org/2001/XMLSchema#string

Liang Dong

http://www.w3.org/2001/XMLSchema#string

Ning Zhu

http://www.w3.org/2001/XMLSchema#string

Peng Zhang

http://www.w3.org/2001/XMLSchema#string

Shengqing Li

http://www.w3.org/2001/XMLSchema#string

Xiujuan Zhang

http://www.w3.org/2001/XMLSchema#string

Youzhi Zhang

http://www.w3.org/2001/XMLSchema#string

Yuanyuan Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow

Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c

ROS1 rearrangements define a unique molecular class of lung cancers.

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort.

The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma.

Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.

The protein tyrosine kinase family of the human genome

The causes and consequences of genetic heterogeneity in cancer evolution

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

P2888

s12890-018-0585-9

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1186/S12890-018-0585-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1100558770

http://www.w3.org/2001/XMLSchema#string

P698

29361925

http://www.w3.org/2001/XMLSchema#string

P932

5781300

http://www.w3.org/2001/XMLSchema#string